Literature DB >> 2369807

Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.

D K Yu1, A T Elvin, B Morrill, L S Eichmeier, R C Lanman, M B Lanman, D H Giesing.   

Abstract

Single doses of 1 gm 5-aminosalicylic acid (5-ASA) suspension was administered to 24 healthy volunteers during both fasting and fed conditions. For subjects in a fasting state, plasma 5-ASA and acetyl 5-ASA concentrations peaked rapidly 1 hour after dosing to 14.72 micrograms/ml and 11.4 micrograms/ml, respectively. The elimination half-life of 5-ASA was 51.9 minutes, whereas the acetyl 5-ASA half-life could not be determined. A mean of 78.3% of the dose was excreted in the urine, with 5-ASA accounting for 21.2% of the dose and acetyl 5-ASA accounting for the balance. Only 11.3% of the dose was eliminated in the feces, consisting mostly of acetyl 5-ASA. Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment. Urinary excretion of the salicylates was reduced to 46.8%, and fecal salicylate elimination increased almost 100%--to 24.2% of the total dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369807     DOI: 10.1038/clpt.1990.113

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

Authors:  P W Lowry; C L Franklin; A L Weaver; M G Pike; D C Mays; W J Tremaine; J J Lipsky; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 3.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 4.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 5.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

6.  Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man.

Authors:  D K Yu; B Morrill; L S Eichmeier; R C Lanman; M B Lanman; D H Giesing; S J Weir
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].

Authors:  J Keller; H Goebell; U Klotz; P Layer
Journal:  Med Klin (Munich)       Date:  1998-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.